• En-Tung Tsai, Huan-Chin Tseng, Yu-Hao Liu, You-Ren Wu, Shih-Yuan Peng, Wei-Yi Lai, Yi-Ying Lin, Shih-Pin Chen, Shih-Hwa Chiou, Yi-Ping Yang, and Yueh Chien.
• Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
• J Chin Med Assoc. 2024 May 1; 87 (5): 488497488-497.

BackgroundMesenchymal stem cells (MSCs) have promising potential in clinical application, whereas their limited amount and sources hinder their bioavailability. Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) have become prominent options in regenerative medicine as both possess the ability to differentiate into MSCs.MethodsRecently, our research team has successfully developed human leukocyte antigen (HLA)-homozygous iPSC cell lines with high immune compatibility, covering 13.5% of the Taiwanese population. As we deepen our understanding of the differences between these ESCs and HLA-homozygous iPSCs, our study focused on morphological observations and flow cytometry analysis of specific surface marker proteins during the differentiation of ESCs and iPSCs into MSCs.ResultsThe results showed no significant differences between the two pluripotent stem cells, and both of them demonstrated the equivalent ability to further differentiate into adipose, cartilage, and bone cells.ConclusionOur research revealed that these iPSCs with high immune compatibility exhibit the same differentiation potential as ESCs, enhancing the future applicability of highly immune-compatible iPSCs.Copyright © 2024, the Chinese Medical Association.

17 keywords...

hide…